Parameters | Training (n = 128) | Testing (n = 57) | P-value |
---|---|---|---|
Age (years, mean ± SD) | 52.83 ± 8.76 | 52.63 ± 9.11 | 0.891 |
BMI (kg/m2, mean ± SD) | 24.80 ± 3.44 | 24.63 ± 3.78 | 0.757 |
SCC-Ag (ng/mL, mean ± SD) | 11.90 ± 22.20 | 11.02 ± 17.99 | 0.792 |
Tumor grade (%) | Â | Â | 0.062 |
Low-grade (well/moderately differentiated) | 81 (63.3%) | 44 (77.2%) | Â |
High-grade (poorly differentiated) | 47 (36.7%) | 13 (22.8%) | Â |
T stage (%) | Â | Â | 0.435 |
  T2 | 98 (76.6%) | 39 (68.4%) |  |
  T3 | 25 (19.5%) | 16 (28.1%) |  |
  T4 | 5 (3.9%) | 2 (3.5%) |  |
2018 FIGO stage (%) | Â | Â | 0.928 |
  II | 64 (50.0%) | 27 (47.4%) |  |
  III | 59 (46.1%) | 28 (49.1%) |  |
  IVA | 5 (3.9%) | 2 (3.5%) |  |
Tumor maximum-diameter (cm, mean ± SD) | 4.49 ± 1.13 | 4.33 ± 1.35 | 0.400 |
LNM position (%) | Â | Â | 0.906 |
  Negative | 74 (57.8%) | 31 (54.4%) |  |
  Pelvic LNM | 40 (31.3%) | 19 (33.3%) |  |
  Para-aortic LNM | 14 (10.9%) | 7 (12.3%) |  |
LNM number (%) | Â | Â | 0.813 |
  0 | 74 (57.8%) | 31 (54.4%) |  |
  ≤2 | 24 (18.8%) | 13 (22.8%) |  |
  >2 | 30 (23.4%) | 13 (22.8%) |  |